Skip to content

Ozone Therapy Research Roundup: Wound Care, Stroke Recovery, and Cancer Support

Ozone Therapy Ozone Therapy ozone therapy stock pictures, royalty-free photos & images

Ozone therapy continues to draw growing peer-reviewed research interest as a complementary tool in integrative medicine. Here’s a roundup of recent notable developments spanning a new wearable delivery device, stroke recovery data, and cancer-support applications.

Table of Contents

  • A Wearable Approach to Drug-Resistant Wounds
  • Stroke Recovery Data
  • Ozone as Complementary Cancer Support
  • Faster Healing for Chronic Facial Wounds
  • Why This Matters
  • Conclusion

A Wearable Approach to Drug-Resistant Wounds

Researchers published a study in Advanced Therapeutics describing a smart wearable ozone therapy system designed to treat multidrug-resistant (MDR) bacterial wound infections. Chronic non-healing wounds affect an estimated 10.5 million people in the US and cost Medicare between $28.1 and $96.8 billion annually, with drug-resistant infections a growing complication as antibiotic resistance rises. The device combines ozone’s antimicrobial action with bio-stimulatory healing effects in a single wearable format, an approach the researchers say outperforms conventional single-mechanism treatments like silver dressings or standalone phototherapy in early testing.

Stroke Recovery Data

A 2025 clinical trial published in Frontiers in Medicine compared ozone therapy against traditional antioxidant drugs in patients recovering from acute ischemic stroke, finding that ozone outperformed the comparator on both neurological recovery measures and safety profile. The proposed mechanism centers on ozone’s activation of HIF-1α (hypoxia-inducible factor 1-alpha), which improves oxygen delivery to tissue affected by reduced blood flow — the same pathway researchers point to in ozone’s effects on other vascular and circulatory conditions, including peripheral artery disease and diabetic foot ulcers.

Ozone as Complementary Cancer Support

A 2025 scoping review evaluated medical ozone as a complementary approach for managing cancer-related pain, fatigue, anxiety, and depression, concluding it shows promise with a favorable safety profile when used alongside standard oncology care. This adds to a body of smaller clinical studies from Spanish research groups examining ozone for cancer-treatment-related pelvic pain and chemotherapy-induced peripheral neuropathy, an area that continues to see active clinical trial enrollment.

Faster Healing for Chronic Facial Wounds

A single-arm clinical study published in the Journal of Maxillofacial and Oral Surgery evaluated topical ozone therapy in 11 patients with chronic facial wounds. Pain scores dropped sharply, from a mean of 7.09 on day one to 2.81 by day three, with no reported pain by day seven. Wound size decreased correspondingly, from 14.3 cm² on day one to 0.68 cm² by day seven — a small study, but a striking healing trajectory that supports larger controlled trials.

Why This Matters

Taken together, these studies reflect a field maturing beyond anecdotal use toward device innovation and rigorous outcome measurement. Evidence quality remains moderate by conventional standards — several of the strongest findings still come from small or single-arm studies — but the mechanistic consistency across wound healing, vascular conditions, and inflammatory pain points to biologically plausible pathways (HIF-1α activation, antimicrobial action, immune modulation) that researchers are now testing more rigorously. For integrative and regenerative practices, this is a field worth watching for practice-relevant protocol updates as larger randomized trials mature.

Conclusion

Ozone therapy research is expanding from established uses in pain and wound care into higher-stakes areas like stroke recovery and oncology support. Larger randomized controlled trials will be the next test of whether these early signals hold up at scale.

Sources

  • Advanced Therapeutics (Wiley), “Smart Wearable Ozone Therapy System for Managing Multidrug-Resistant Wound Infections” — Read here
  • Journal of Maxillofacial and Oral Surgery (Springer Nature), “Role of Topical Ozone Therapy in the Management of Chronic Facial Wounds: A Single-Arm Clinical Study” — Read here
  • TopDoctor Magazine, “Ozone Therapy: The Complete Science-Backed Guide (2026)” — Read here
Posted in What We Treat | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Ozone Therapy Research Roundup: Wound Care, Stroke Recovery, and Cancer Support

FDA Advisory Committee to Review Cell Therapy for Duchenne Muscular Dystrophy

The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee meets July 29 to review Capricor Therapeutics’ deramiocel, an investigational allogeneic cell therapy for Duchenne muscular dystrophy. The meeting comes ahead of an August 22 target decision date and follows a prior rejection of the company’s first application.

Table of Contents

  • What’s Happening
  • How Deramiocel Works
  • What the Data Show
  • Why This Matters
  • Conclusion

What’s Happening

On July 29, 2026, the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee will convene to review Capricor Therapeutics’ Biologics License Application for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD). The Federal Register notice confirming the meeting’s final details was amended on July 24, 2026, and the session will be livestreamed for public viewing.

This is Capricor’s second attempt at approval. The FDA rejected the company’s original application, based primarily on Phase 2 data, with a complete response letter citing substantial-evidence and manufacturing (CMC) deficiencies. The agency has since rescinded that letter and is now reviewing a resubmitted application built on additional Phase 3 data, with a PDUFA target action date of August 22, 2026.

How Deramiocel Works

Deramiocel (also known as CAP-1002) is an allogeneic, off-the-shelf cell therapy made from human cardiosphere-derived cells. Administered by infusion, it’s designed to reduce inflammation and support tissue repair in both skeletal and cardiac muscle — the two systems progressively damaged by DMD. If approved, it would be the first therapy to address both the skeletal and cardiac manifestations of the disease in a single product, a distinction that matters given that cardiomyopathy is a leading cause of death in DMD patients.

Deramiocel holds Orphan Drug designation in both the US and EU, Regenerative Medicine Advanced Therapy (RMAT) and Rare Pediatric Disease designations in the US, and Advanced Therapy Medicinal Product (ATMP) status in the EU — the last of which may qualify Capricor for a Priority Review Voucher if approved.

What the Data Show

The resubmitted BLA is supported by the Phase 2 HOPE-2 trial and its long-term HOPE-2-OLE extension, along with topline results from the Phase 3 HOPE-3 trial. HOPE-2 showed a 36.2% benefit on a mid-level elbow measure of upper limb function (PUL) versus placebo at 12 months, along with reduced cardiac injury markers (CK-MB and total CK), suggesting less myocardial damage.

HOPE-3 met its primary endpoint, showing a 54% slowing of disease progression on the PUL v2.0 scale, and its key cardiac endpoint showed a 91% slowing in the decline of left ventricular ejection fraction (LVEF) by central cardiac MRI — a marker of heart muscle function. The trial also met additional controlled secondary endpoints.

Why This Matters

For the regenerative and integrative medicine community, this advisory committee meeting is a bellwether moment for cell therapy in a devastating pediatric disease with no treatment that addresses both its muscular and cardiac components. An advisory committee’s recommendation isn’t binding, but it heavily influences the FDA’s final decision and signals how regulators are weighing benefit-risk tradeoffs for allogeneic cell products more broadly. A second look at a previously rejected application, now backed by Phase 3 data, also illustrates how sponsors are increasingly able to iterate through FDA’s regenerative medicine pathways rather than face a single make-or-break review.

Conclusion

The July 29 advisory committee meeting is a critical checkpoint on deramiocel’s path to potential approval by August 22. A positive recommendation would move a first-in-class dual-benefit cell therapy closer to patients; a negative one would raise fresh questions about the regulatory bar for allogeneic cell products in rare pediatric disease.

Sources

  • NeurologyLive, “FDA Advisory Committee Schedules Meeting to Review Deramiocel’s BLA in Duchenne Muscular Dystrophy” — Read here
  • GlobeNewswire / Capricor Therapeutics, “Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy” — Read here
  • Federal Register, “Cellular, Tissue, and Gene Therapies Advisory Committee; Amendment of Notice” — Read here
Posted in What We Treat | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on FDA Advisory Committee to Review Cell Therapy for Duchenne Muscular Dystrophy

FDA Approves Tregzi, First Regulatory T-Cell Therapy to Reduce Chronic GVHD

The FDA has approved Tregzi, a precision-engineered cell therapy from Orca Bio, as the first regulatory T-cell (Treg) based treatment for adults undergoing allogeneic stem cell transplants for blood cancers. Trial data showed it more than doubled one-year survival free of chronic graft-versus-host disease compared with standard transplants.

Table of Contents

  • What Happened
  • How Tregzi Works
  • What the Data Show
  • Why This Matters
  • Conclusion

What Happened

On June 30, 2026, the FDA approved Tregzi (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq), developed by Orca Bio and previously known as Orca-T. It is indicated for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (GVHD)-free survival in adults with hematologic malignancies. The approval makes Tregzi the first FDA-cleared therapy built on highly purified regulatory T cells, and only the second cell therapy ever approved specifically in the GVHD setting, following Mesoblast’s Ryoncil.

Tregzi received Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations ahead of filing, along with Priority Review. The FDA’s target action date was extended from April to July 2026 after the agency requested additional manufacturing information.

How Tregzi Works

Tregzi reformulates a standard allogeneic stem cell transplant rather than replacing it outright. Instead of infusing an unmodified mix of stem and immune cells from a matched donor, it separates the donor material into components: hematopoietic stem and progenitor cells to rebuild the patient’s blood and immune system, highly purified regulatory T cells to suppress the immune attack that causes GVHD, and a follow-up dose of conventional T cells to help clear residual cancer cells. The goal is to preserve the beneficial graft-versus-leukemia effect of a transplant while reducing the collateral immune damage that has long made GVHD one of the field’s most difficult trade-offs.

What the Data Show

Approval was based on the Phase 3 PRECISION-T trial, a randomized, open-label study of 187 adults with blood cancers, including acute leukemia and myelodysplastic syndrome, across 19 transplant centers. Patients received either Tregzi with single-agent tacrolimus, or a standard transplant with a combination of tacrolimus and methotrexate.

At one year, 78.0% of Tregzi recipients achieved chronic GVHD-free survival, compared with 38.4% in the standard transplant group. After accounting for death as a competing risk, serious chronic GVHD developed in 12.6% of Tregzi patients versus 44.0% of controls. Safety data also favored Tregzi: Grade 3 or 4 acute GVHD at day 180 occurred in 6% of Tregzi recipients versus 10% with standard transplant, alongside fewer serious infections.

Why This Matters<

Posted in What We Treat | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on FDA Approves Tregzi, First Regulatory T-Cell Therapy to Reduce Chronic GVHD

FDA Grants RMAT Status to Allocetra, a Cell Therapy for Knee Osteoarthritis

FDA Grants RMAT Status to Allocetra, a Cell Therapy for Knee Osteoarthritis

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra, an investigational cell therapy from Enlivex, for age-related symptomatic knee osteoarthritis in adults 64 and older. The designation is based on six-month data showing durable improvements in pain and function.

What Happened

The FDA has granted Regenerative Medicine Advanced Therapy designation to Allocetra, Enlivex’s clinical-stage cell therapy, for the treatment of age-related symptomatic knee osteoarthritis in patients aged 64 and older. RMAT designation, created under the 21st Century Cures Act, is reserved for cell and gene therapies that show potential to treat, modify, reverse, or cure a condition with significant unmet need, combining the benefits of fast track and breakthrough therapy designations, including intensive early FDA engagement and potential eligibility for accelerated approval and priority review.

Enlivex CEO Oren Hershkovitz said the designation reflects the strength of the company’s clinical data and its decision to concentrate development on the age group that showed the strongest response in its Phase I/IIa trial.

How Allocetra Works

Allocetra is an allogeneic, off-the-shelf cell therapy composed of donor-derived apoptotic cells. Rather than replacing damaged joint tissue directly, it works by reprogramming macrophages — immune cells that drive chronic joint inflammation — back into a homeostatic state. That approach targets inflammation at its source rather than simply managing symptoms, distinguishing it from existing osteoarthritis treatments, none of which are FDA- or EMA-approved to slow or reverse structural joint damage.

A similar rationale supported RMAT designation for Genascence’s GNSC-001, a gene therapy for knee osteoarthritis, roughly a year earlier in July 2025 — suggesting regulators are increasingly receptive to therapies aimed at OA’s underlying inflammatory drivers rather than pain control alone.

What the Data Show

Three-month data reported in August 2025 showed that in patients 60 and older, Allocetra produced substantial reductions in pain and improvements in function compared with placebo, with the effect size correlating positively with age. Six-month follow-up data, reported in November 2025, confirmed the effect held: on a composite pain-and-function endpoint, patients 61 and older receiving Allocetra improved by 27.8 points versus 15.5 points in the placebo group — an 80% improvement over placebo (p=0.02).

Enlivex is now enrolling a global, multicenter, randomized, double-blind, placebo-controlled Phase IIb trial in the same age-related OA population, with active sites in the US, Denmark, and Poland.

Why This Matters

For practitioners and patients in regenerative and integrative medicine, this designation is a signal worth tracking. Knee osteoarthritis is one of the most common reasons patients seek non-surgical regenerative options — PRP, prolotherapy, and related injection therapies — precisely because standard treatments only manage pain rather than address the underlying joint inflammation. A therapy designed to reprogram immune signaling rather than mask symptoms represents a meaningful shift in how the condition could eventually be approached in mainstream care, and RMAT status means the FDA pathway toward approval could move faster than the standard track. It’s still investigational and years from being available to patients, but it reinforces that immune modulation — not just tissue replacement — is becoming a serious avenue in regenerative orthopedics.

Conclusion

Allocetra’s RMAT designation doesn’t change treatment options today, but it marks another concrete step for immune-based regenerative therapies moving through FDA review. With Phase IIb enrollment underway at US sites, this is a story worth revisiting as new data emerges.

Sources

  • BioPharm International, “Enlivex’s Allocetra Wins FDA RMAT Designation for Age-Related Knee Osteoarthritis” — Read here
  • BioPharm International, “The BioPharm Brief: Regeneration, Responses, and Regulatory Wins” — Read here
Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on FDA Grants RMAT Status to Allocetra, a Cell Therapy for Knee Osteoarthritis

Beyond Mold: A Complete Guide to Biotoxin Illness (CIRS) and How to Recover

Close-up of a weathered wall with cracks and green algae, texture details.

If you have spent months or years cycling through specialists, collecting vague diagnoses like fibromyalgia or chronic fatigue syndrome, and feeling as though your body has become a stranger to you, you are not alone. You may be dealing with Biotoxin Illness/CIRS, a condition rooted in a genetic quirk that affects roughly 25 percent of the population. The experience is often isolating and frightening, but the science behind it is clear, and effective treatment exists. In humid regions like Florida, where water-damaged buildings are distressingly common, understanding this condition is not just academic; it is a practical necessity for reclaiming your health.

Table of Contents

What Is Biotoxin Illness (CIRS)? The 25% Problem

Chronic Inflammatory Response Syndrome (CIRS) is not a simple mold allergy. It is a multi-system, multi-symptom inflammatory illness driven by a genetic susceptibility in the immune system. Specifically, about one in four people carry certain HLA-DR genotypes that prevent their immune cells from effectively recognizing and clearing biotoxins from the body. When a genetically susceptible person is exposed to a biotoxin, their innate immune system launches a chronic, unrelenting inflammatory response. The toxin is never properly tagged for removal, so it remains in the tissues, keeping the body in a state of low-grade, systemic fire.

The triggers for this cascade are broader than many people realize. The most common culprit is mold and mycotoxins from water-damaged buildings, but the list also includes the bacteria responsible for Lyme disease (Borrelia burgdorferi), dinoflagellates like those causing ciguatera poisoning from reef fish, and other environmental contaminants. This is not a respiratory condition limited to sneezing and wheezing. CIRS is a whole-body inflammatory illness that can disrupt nearly every system, from neurological function to hormone production.

The 37 Symptoms: Why You Feel So Terrible

One of the most bewildering aspects of CIRS is the sheer number and variety of symptoms it can produce. The condition is associated with 37 or more symptoms, which researchers have organized into 13 distinct clusters. If a person exhibits symptoms in eight of those 13 clusters, CIRS becomes a strong diagnostic possibility. This is not a condition that announces itself with a single, clear sign; it is a storm that hits from multiple directions at once.

The most debilitating symptoms often include profound brain fog, memory loss, and difficulty concentrating. Physical symptoms can range from crushing fatigue and joint pain without visible swelling to unusual sensations like static shocks when touching metal or “ice pick” pains that come and go without warning. Chronic sinus congestion, shortness of breath, and a persistent cough are also common. Because these symptoms span so many medical specialties, patients often find themselves shuffled from neurologist to rheumatologist to psychiatrist, with no one connecting the dots.

This fragmentation leads to what many patients describe as medical gaslighting. Standard lab panels, including complete blood counts, comprehensive metabolic profiles, and autoimmune markers, typically return normal. When the tests are normal but the patient is clearly suffering, the default explanation is too often anxiety, depression, or a psychosomatic disorder. If you have been told “it’s all in your head,” the science of CIRS says it is actually in your cells, driven by a measurable inflammatory cascade that standard labs are not designed to detect.

How Is CIRS Diagnosed? The Specific Biomarker Panel

Because standard blood work is essentially useless for identifying CIRS, diagnosis requires a targeted functional medicine panel based on the Shoemaker protocol. This is not about guessing; it is about measuring the specific inflammatory and hormonal markers that become dysregulated in this condition. The critical biomarkers include melanocyte-stimulating hormone (MSH), which is typically low; vasoactive intestinal polypeptide (VIP), also low; antidiuretic hormone (ADH), often low; transforming growth factor beta-1 (TGF-beta 1), which runs high; matrix metalloproteinase-9 (MMP-9), high; vascular endothelial growth factor (VEGF), low; and complement C4a, which is markedly elevated. This pattern of highs and lows paints a clear picture of a body stuck in a chronic inflammatory state.

Beyond blood work, there is a simple, inexpensive screening tool called the Visual Contrast Sensitivity (VCS) test. This test measures your ability to detect subtle differences in shades of gray, a neurological function that is often impaired by neurotoxins. It is not a definitive diagnostic tool on its own, but it is an excellent way to track the severity of neuroinflammation and monitor progress during treatment.

Another critical piece of the diagnostic puzzle is a nasal swab to check for Multiple Antibiotic Resistant Coagulase Negative Staphylococci, or MARCoNS. This resistant staph infection colonizes the deep nasal passages in many CIRS patients and actively suppresses MSH production, perpetuating the illness. Identifying and eradicating MARCoNS is a non-negotiable step before the final phase of treatment can begin. At INTEGRAL Medicine, we use the full Shoemaker protocol biomarker panel to get you answers, not guesses.

The Treatment Roadmap: From Source Removal to VIP

Treating CIRS is a methodical, step-by-step process. Skipping steps or rushing to the finish line almost always backfires. The protocol is designed to remove the source of the toxins, bind and eliminate the circulating toxins, clear any secondary infections, and finally repair the damage done to the brain and endocrine system.

Step 1: Source Removal (The Non-Negotiable)

You cannot heal while living or working in a water-damaged building. Studies suggest that up to 50 percent of buildings in the United States have some degree of water damage, making this a widespread and often hidden problem. The first and most critical step is to identify and either remediate or leave the contaminated environment. Practical steps include running an ERMI (Environmental Relative Moldiness Index) dust test on your home, hiring a qualified professional for a thorough mold inspection, and addressing the root causes of moisture intrusion. For those wondering how to get rid of mycotoxins in a home, the checklist includes repairing all leaks, maintaining indoor humidity below 50 percent with dehumidifiers, using HEPA air filters, and properly cleaning or discarding porous items that cannot be fully remediated.

Step 2: Binding and Elimination (The Shoemaker Protocol)

Once you are in a clean environment, the next phase focuses on pulling biotoxins out of the body. This is done with binders, substances that attach to toxins in the gut and prevent them from being reabsorbed. The gold standard binder is cholestyramine (CSM), a prescription medication, but activated charcoal, bentonite clay, and other natural binders are also used depending on the patient’s tolerance and needs.

A more advanced approach involves what is known as the lipid-exchange method. Because biotoxins are lipophilic, meaning they store themselves in fatty tissues, simply binding toxins in the gut is sometimes not enough. Using agents like phosphatidylcholine and specific fatty acids helps mobilize stored toxins from fat cells so they can be bound and eliminated. This addresses a common question: how long do mycotoxins stay in the body? The answer varies based on genetics, the total toxic load, and treatment compliance, but active binding and mobilization typically continue for six to eighteen months before the body’s burden is sufficiently reduced.

Step 3: Nasal Treatment (MARCoNS Eradication)

Before the body can truly begin to repair, the MARCoNS infection must be addressed. This typically involves a compounded nasal spray, often containing Bactroban, EDTA, and gentamicin (known as BEG spray), which is used for several weeks. This step is crucial because MARCoNS produces a biofilm in the nasal passages and actively suppresses MSH, a master hormone that regulates inflammation, sleep, and pain perception. Leaving MARCoNS untreated will block the neuroendocrine repair that is the ultimate goal of treatment.

Step 4: VIP Spray (The Repair Phase)

The final step in the core protocol is the use of Vasoactive Intestinal Polypeptide (VIP), a naturally occurring neuropeptide. In CIRS, VIP levels are typically very low. Replacing VIP with a prescription nasal spray helps repair the blood-brain barrier, restore normal sleep architecture, normalize hormone levels, and reduce the chronic inflammatory response. A critical caution: VIP should never be used until the source has been removed, binders have reduced the toxin load, and MARCoNS has been eradicated. Using it too early can actually worsen symptoms by mobilizing toxins in a body that is not yet ready to clear them.

Beyond the Protocol: Advanced Therapies for Stubborn Cases

For many patients, the Shoemaker protocol is life-changing. But some individuals, particularly those with very high toxic loads, long exposure histories, or additional complicating factors, need a deeper toolkit. This is where an integrative approach becomes essential. Advanced modalities can include ozone therapy to modulate the immune system and improve oxygen utilization, far infrared sauna to enhance detoxification through sweating, and Low-Dose Immunotherapy (LDI) to retrain the immune system’s overactive response to triggers.

Another often-overlooked factor is the role of implanted materials and chronic infections. Dental implants, root canals, or even old surgical mesh can act as reservoirs for biotoxins or trigger a cross-reactive inflammatory response. Similarly, chronic viral infections like Epstein-Barr, Herpes, or an overgrowth of Candida can keep the immune system in a state of perpetual alarm, mimicking or compounding CIRS. The CranioBiotic Technique (CBT) is another tool for addressing these hidden stressors. If you have tried the standard protocol and still feel stuck, we have a deeper toolkit. We do not give up on you.

What Is the Prognosis? Can You Fully Recover?

Honest conversations about outcomes are important. CIRS is a chronic condition that requires ongoing awareness and management, much like managing an autoimmune disease. The goal is not necessarily a permanent “cure” in the sense that you can return to a moldy building without consequence. However, with proper treatment, the vast majority of patients see a 70 to 90 percent improvement in their quality of life. The recovery timeline is variable, typically ranging from six months to two years for significant improvement, depending on the severity and duration of the exposure and the individual’s genetic makeup. Long-term management involves avoiding re-exposure, periodic VCS testing to catch any early signs of relapse, and possibly using binders intermittently after known or suspected exposures.

Frequently Asked Questions About Biotoxin Illness/CIRS

Is CIRS a real disease? This question arises because CIRS is still gaining recognition in mainstream medicine. The answer is yes. The Shoemaker protocol is built on decades of peer-reviewed research, and the CDC acknowledges the serious health effects of mold exposure in water-damaged buildings. The specific biomarkers and treatment steps are well-documented in the scientific literature.

Can I treat CIRS without leaving my home? No. If your home is the source of the biotoxins, source removal is mandatory. This may mean a temporary relocation during remediation or, in severe cases, a permanent move. There is no binder or supplement that can outrun a continuously contaminated environment.

Does insurance cover CIRS treatment? This is a significant challenge. While some office visits and standard labs may be covered, many of the specialized biomarker tests and compounded medications are not fully reimbursed by insurance. We encourage you to schedule a consultation to discuss your specific situation and explore financial options transparently.

Can children get CIRS? Yes, children are absolutely susceptible, though their symptoms may look different. In pediatric cases, CIRS can present as behavioral issues, ADHD-like symptoms, chronic ear infections, or developmental delays. The same principles of diagnosis and treatment apply, though the approach is modified for a child’s physiology.

Why Choose INTEGRAL Medicine for CIRS Treatment?

Living in the Sarasota and Bradenton area means living with high humidity and a built environment that is uniquely vulnerable to water damage. We understand the specific environmental triggers of this region and how they contribute to Biotoxin Illness/CIRS. Our approach combines the rigorous, evidence-based Shoemaker protocol with advanced functional medicine therapies like ozone, sauna, and LDI to address even the most stubborn cases. Most importantly, we listen to your story with warmth and respect. We know your symptoms are real, and we have the tools to help. Schedule a consultation today to start your biomarker testing and get your life back.

Posted in What We Treat | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Beyond Mold: A Complete Guide to Biotoxin Illness (CIRS) and How to Recover
941-444-6336 Directions